1. Home
  2. GLDD vs ABUS Comparison

GLDD vs ABUS Comparison

Compare GLDD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Great Lakes Dredge & Dock Corporation

GLDD

Great Lakes Dredge & Dock Corporation

HOLD

Current Price

$17.01

Market Cap

1.1B

Sector

Industrials

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.61

Market Cap

929.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLDD
ABUS
Founded
1890
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
929.6M
IPO Year
2007
2008

Fundamental Metrics

Financial Performance
Metric
GLDD
ABUS
Price
$17.01
$4.61
Analyst Decision
Sell
Strong Buy
Analyst Count
2
1
Target Price
$17.00
$5.00
AVG Volume (30 Days)
1.8M
1.9M
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
28.57
55.26
EPS
1.08
N/A
Revenue
$702,503,000.00
$14,083,000.00
Revenue This Year
$5.19
N/A
Revenue Next Year
$7.56
$783.24
P/E Ratio
$15.74
N/A
Revenue Growth
N/A
128.21
52 Week Low
$8.49
$3.04
52 Week High
$17.02
$5.10

Technical Indicators

Market Signals
Indicator
GLDD
ABUS
Relative Strength Index (RSI) 68.41 55.64
Support Level $14.60 $4.19
Resistance Level N/A $4.64
Average True Range (ATR) 0.03 0.19
MACD -0.06 0.03
Stochastic Oscillator 80.00 76.61

Price Performance

Historical Comparison
GLDD
ABUS

About GLDD Great Lakes Dredge & Dock Corporation

Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: